| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Enzalutamide in metastatic prostate cancer before chemotherapy.
|
N Engl J Med
|
2014
|
11.05
|
|
2
|
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
|
BJU Int
|
2006
|
3.39
|
|
3
|
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
|
J Natl Cancer Inst
|
2012
|
3.37
|
|
4
|
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
|
J Urol
|
2002
|
2.02
|
|
5
|
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
|
Scand J Urol Nephrol
|
2008
|
1.74
|
|
6
|
The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
|
Urology
|
2012
|
1.53
|
|
7
|
Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study.
|
BJU Int
|
2013
|
1.46
|
|
8
|
[Screening for prostate cancer--what does the evidence show?].
|
Ugeskr Laeger
|
2007
|
1.41
|
|
9
|
[Cryotherapy of prostatic cancer].
|
Ugeskr Laeger
|
2011
|
1.39
|
|
10
|
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
|
J Urol
|
2004
|
1.31
|
|
11
|
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma.
|
Prostate
|
2006
|
1.24
|
|
12
|
Brain energy metabolism and blood flow differences in healthy aging.
|
J Cereb Blood Flow Metab
|
2012
|
1.20
|
|
13
|
Normalization in PET group comparison studies--the importance of a valid reference region.
|
Neuroimage
|
2008
|
1.12
|
|
14
|
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
|
Int J Cancer
|
2005
|
1.12
|
|
15
|
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
|
Scand J Urol Nephrol
|
2002
|
1.10
|
|
16
|
Active surveillance for clinically localized prostate cancer--a systematic review.
|
J Surg Oncol
|
2014
|
1.09
|
|
17
|
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
|
Scand J Urol
|
2013
|
0.96
|
|
18
|
Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
|
Clin Cancer Res
|
2007
|
0.93
|
|
19
|
Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy--an analysis of 1105 patients.
|
Urology
|
2005
|
0.93
|
|
20
|
Active surveillance can reduce overtreatment in patients with low-risk prostate cancer.
|
Dan Med J
|
2013
|
0.92
|
|
21
|
Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer.
|
BJU Int
|
2011
|
0.90
|
|
22
|
Is it possible to predict low-volume and insignificant prostate cancer by core needle biopsies?
|
APMIS
|
2012
|
0.87
|
|
23
|
Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
|
Prostate
|
2010
|
0.87
|
|
24
|
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
|
Scand J Urol Nephrol
|
2011
|
0.87
|
|
25
|
Synthesis of neurotransmitter GABA via the neuronal tricarboxylic acid cycle is elevated in rats with liver cirrhosis consistent with a high GABAergic tone in chronic hepatic encephalopathy.
|
J Neurochem
|
2011
|
0.87
|
|
26
|
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
|
BJU Int
|
2006
|
0.87
|
|
27
|
Metabolic fate of isoleucine in a rat model of hepatic encephalopathy and in cultured neural cells exposed to ammonia.
|
Metab Brain Dis
|
2008
|
0.86
|
|
28
|
No oxygen delivery limitation in hepatic encephalopathy.
|
Metab Brain Dis
|
2010
|
0.84
|
|
29
|
Chemotherapeutic prevention studies of prostate cancer.
|
J Urol
|
2004
|
0.84
|
|
30
|
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
|
Radiother Oncol
|
2005
|
0.83
|
|
31
|
The metabolic role of isoleucine in detoxification of ammonia in cultured mouse neurons and astrocytes.
|
Neurochem Int
|
2007
|
0.83
|
|
32
|
[Prostatic cancer 2006--status and new challenges. The Danish Society of Urology].
|
Ugeskr Laeger
|
2006
|
0.82
|
|
33
|
Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer.
|
BJU Int
|
2013
|
0.81
|
|
34
|
[Prostate cancer in Denmark 1943-2002].
|
Ugeskr Laeger
|
2007
|
0.81
|
|
35
|
[Organisation and early outcome after radical prostatectomy in Denmark 2004-2007].
|
Ugeskr Laeger
|
2008
|
0.80
|
|
36
|
Primary Gleason pattern in biopsy Gleason score 7 is predictive of adverse histopathological features and biochemical failure following radical prostatectomy.
|
Scand J Urol
|
2013
|
0.80
|
|
37
|
Repeated biopsies in patients with prostate cancer on active surveillance: clinical implications of interobserver variation in histopathological assessment.
|
BJU Int
|
2014
|
0.80
|
|
38
|
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
|
Expert Rev Anticancer Ther
|
2009
|
0.80
|
|
39
|
Variable ATP yields and uncoupling of oxygen consumption in human brain.
|
Adv Exp Med Biol
|
2011
|
0.80
|
|
40
|
Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.
|
Eur J Cancer
|
2013
|
0.79
|
|
41
|
Active surveillance for localized prostate cancer: an analysis of patient contacts and utilization of healthcare resources.
|
Scand J Urol
|
2014
|
0.78
|
|
42
|
[Early complications following open radical prostatectomy].
|
Ugeskr Laeger
|
2009
|
0.78
|
|
43
|
Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.
|
Endocr Relat Cancer
|
2013
|
0.78
|
|
44
|
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
|
Clin Chem Lab Med
|
2012
|
0.78
|
|
45
|
Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer.
|
Scand J Urol
|
2014
|
0.78
|
|
46
|
Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation.
|
APMIS
|
2011
|
0.78
|
|
47
|
Distribution of PK11195 binding sites in porcine brain studied by autoradiography in vitro and by positron emission tomography.
|
Synapse
|
2006
|
0.77
|
|
48
|
Radical prostatectomy in clinically localized high-risk prostate cancer: outcome of 231 consecutive patients.
|
Scand J Urol
|
2012
|
0.77
|
|
49
|
First Danish single-institution experience with radical prostatectomy: impact of surgical margins on biochemical outcome.
|
Scand J Urol Nephrol
|
2012
|
0.77
|
|
50
|
Risk factors associated with positive surgical margins following radical prostatectomy for clinically localized prostate cancer: can nerve-sparing surgery increase the risk?
|
Scand J Urol
|
2012
|
0.76
|
|
51
|
Non-apical positive surgical margins after radical prostatectomy for pT2 prostate cancer is associated with the highest risk of recurrence.
|
J Surg Oncol
|
2014
|
0.76
|
|
52
|
[Cryotherapy of prostatic cancer].
|
Ugeskr Laeger
|
2011
|
0.75
|
|
53
|
[Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients].
|
Ugeskr Laeger
|
2008
|
0.75
|
|
54
|
First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients.
|
Prostate Cancer
|
2010
|
0.75
|
|
55
|
[Comment to the status article about denosumab].
|
Ugeskr Laeger
|
2011
|
0.75
|
|
56
|
Monitoring Kidney Function in Neuroendocrine Tumor Patients Treated with (90)Y-DOTATOC: Associations with Risk Factors.
|
Curr Radiopharm
|
2015
|
0.75
|
|
57
|
Patients undergoing radical prostatectomy have a better survival than the background population.
|
Dan Med J
|
2013
|
0.75
|
|
58
|
[Metastatic prostatic cancer].
|
Ugeskr Laeger
|
2003
|
0.75
|
|
59
|
[Diagnosis of prostatic cancer--transrectal biopsy].
|
Ugeskr Laeger
|
2011
|
0.75
|
|
60
|
Early biochemical recurrence, urinary continence and potency outcomes following robot-assisted radical prostatectomy.
|
Scand J Urol
|
2014
|
0.75
|
|
61
|
Risk of biochemical recurrence and positive surgical margins in patients with pT2 prostate cancer undergoing radical prostatectomy.
|
J Surg Oncol
|
2013
|
0.75
|
|
62
|
[Treatment of localised prostate cancer].
|
Ugeskr Laeger
|
2007
|
0.75
|
|
63
|
Robot-assisted radical prostatectomy is a safe procedure.
|
Dan Med J
|
2013
|
0.75
|
|
64
|
Antibiotic prophylaxis and complications following prostate biopsies - a systematic review.
|
Dan Med J
|
2017
|
0.75
|
|
65
|
[The prince on the chestnut].
|
Ugeskr Laeger
|
2007
|
0.75
|
|
66
|
C-type natriuretic peptide in prostate cancer.
|
APMIS
|
2009
|
0.75
|
|
67
|
Length of life gained with surgical treatment of prostate cancer: A population-based analysis.
|
Scand J Urol
|
2014
|
0.75
|
|
68
|
[Prostatic Cancer Patient Association PROPA--and information about prostatic cancer].
|
Ugeskr Laeger
|
2008
|
0.75
|
|
69
|
C-type natriuretic peptide and its precursor: potential markers in human prostate cancer.
|
Biomark Med
|
2015
|
0.75
|
|
70
|
Changes in preoperative characteristics in patients undergoing radical prostatectomy--a 16-year nationwide analysis.
|
Acta Oncol
|
2013
|
0.75
|
|
71
|
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.
|
J Urol
|
2004
|
0.75
|
|
72
|
[Radical prostatectomy in patients with advanced prostate cancer].
|
Ugeskr Laeger
|
2012
|
0.75
|
|
73
|
[New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
|
Ugeskr Laeger
|
2013
|
0.75
|
|
74
|
[Prostatic cancer screening].
|
Ugeskr Laeger
|
2002
|
0.75
|
|
75
|
[Therapeutic vaccines is a novel approach in castration-resistant prostate cancer treatment].
|
Ugeskr Laeger
|
2015
|
0.75
|
|
76
|
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.
|
J Urol
|
2003
|
0.75
|